313 related articles for article (PubMed ID: 15026352)
1. Choice of oxygen-conserving treatment regimen determines the inflammatory response and outcome of photodynamic therapy of tumors.
Henderson BW; Gollnick SO; Snyder JW; Busch TM; Kousis PC; Cheney RT; Morgan J
Cancer Res; 2004 Mar; 64(6):2120-6. PubMed ID: 15026352
[TBL] [Abstract][Full Text] [Related]
2. Photodynamic therapy creates fluence rate-dependent gradients in the intratumoral spatial distribution of oxygen.
Busch TM; Wileyto EP; Emanuele MJ; Del Piero F; Marconato L; Glatstein E; Koch CJ
Cancer Res; 2002 Dec; 62(24):7273-9. PubMed ID: 12499269
[TBL] [Abstract][Full Text] [Related]
3. Measurement of Cyanine Dye Photobleaching in Photosensitizer Cyanine Dye Conjugates Could Help in Optimizing Light Dosimetry for Improved Photodynamic Therapy of Cancer.
James NS; Cheruku RR; Missert JR; Sunar U; Pandey RK
Molecules; 2018 Jul; 23(8):. PubMed ID: 30042350
[TBL] [Abstract][Full Text] [Related]
4. Effect of irradiation fluence rate on the efficacy of photodynamic therapy and tumor oxygenation in meta-tetra (hydroxyphenyl) chlorin (mTHPC)-sensitized HT29 xenografts in nude mice.
Coutier S; Bezdetnaya LN; Foster TH; Parache RM; Guillemin F
Radiat Res; 2002 Sep; 158(3):339-45. PubMed ID: 12175311
[TBL] [Abstract][Full Text] [Related]
5. Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy.
Seshadri M; Spernyak JA; Mazurchuk R; Camacho SH; Oseroff AR; Cheney RT; Bellnier DA
Clin Cancer Res; 2005 Jun; 11(11):4241-50. PubMed ID: 15930363
[TBL] [Abstract][Full Text] [Related]
6. Potentiation of photodynamic therapy antitumor activity in mice by nitric oxide synthase inhibition is fluence rate dependent.
Henderson BW; Sitnik-Busch TM; Vaughan LA
Photochem Photobiol; 1999 Jul; 70(1):64-71. PubMed ID: 10420844
[TBL] [Abstract][Full Text] [Related]
7. The effect of fluence rate on tumor and normal tissue responses to photodynamic therapy.
Sitnik TM; Henderson BW
Photochem Photobiol; 1998 Apr; 67(4):462-6. PubMed ID: 9559590
[TBL] [Abstract][Full Text] [Related]
8. Photodynamic therapy for malignant mesothelioma: preclinical studies for optimization of treatment protocols.
Schouwink H; Ruevekamp M; Oppelaar H; van Veen R; Baas P; Stewart FA
Photochem Photobiol; 2001 Apr; 73(4):410-7. PubMed ID: 11332037
[TBL] [Abstract][Full Text] [Related]
9. Effect of photosensitizer dose on fluence rate responses to photodynamic therapy.
Wang HW; Rickter E; Yuan M; Wileyto EP; Glatstein E; Yodh A; Busch TM
Photochem Photobiol; 2007; 83(5):1040-8. PubMed ID: 17880498
[TBL] [Abstract][Full Text] [Related]
10. Fluence rate as a modulator of PDT mechanisms.
Henderson BW; Busch TM; Snyder JW
Lasers Surg Med; 2006 Jun; 38(5):489-93. PubMed ID: 16615136
[TBL] [Abstract][Full Text] [Related]
11. Role of cytokines in photodynamic therapy-induced local and systemic inflammation.
Gollnick SO; Evans SS; Baumann H; Owczarczak B; Maier P; Vaughan L; Wang WC; Unger E; Henderson BW
Br J Cancer; 2003 Jun; 88(11):1772-9. PubMed ID: 12771994
[TBL] [Abstract][Full Text] [Related]
12. Depletion of tumor oxygenation during photodynamic therapy: detection by the hypoxia marker EF3 [2-(2-nitroimidazol-1[H]-yl)-N-(3,3,3-trifluoropropyl)acetamide ].
Busch TM; Hahn SM; Evans SM; Koch CJ
Cancer Res; 2000 May; 60(10):2636-42. PubMed ID: 10825135
[TBL] [Abstract][Full Text] [Related]
13. Reduction of tumour oxygenation during and after photodynamic therapy in vivo: effects of fluence rate.
Sitnik TM; Hampton JA; Henderson BW
Br J Cancer; 1998 May; 77(9):1386-94. PubMed ID: 9652753
[TBL] [Abstract][Full Text] [Related]
14. Fluence rate-dependent intratumor heterogeneity in physiologic and cytotoxic responses to Photofrin photodynamic therapy.
Busch TM; Xing X; Yu G; Yodh A; Wileyto EP; Wang HW; Durduran T; Zhu TC; Wang KK
Photochem Photobiol Sci; 2009 Dec; 8(12):1683-93. PubMed ID: 20024165
[TBL] [Abstract][Full Text] [Related]
15. Reactive oxygen species explicit dosimetry to predict tumor growth for benzoporphyrin derivative-mediated vascular photodynamic therapy.
Sheng T; Ong YH; Guo W; Zhu T
J Biomed Opt; 2020 Jan; 25(6):1-13. PubMed ID: 31912689
[TBL] [Abstract][Full Text] [Related]
16. Increasing damage to tumor blood vessels during motexafin lutetium-PDT through use of low fluence rate.
Busch TM; Wang HW; Wileyto EP; Yu G; Bunte RM
Radiat Res; 2010 Sep; 174(3):331-40. PubMed ID: 20726728
[TBL] [Abstract][Full Text] [Related]
17. Fluence plays a critical role on the subsequent distribution of chemotherapy and tumor growth delay in murine mesothelioma xenografts pre-treated by photodynamic therapy.
Wang Y; Wang X; Le Bitoux MA; Wagnieres G; Vandenbergh H; Gonzalez M; Ris HB; Perentes JY; Krueger T
Lasers Surg Med; 2015 Apr; 47(4):323-30. PubMed ID: 25639847
[TBL] [Abstract][Full Text] [Related]
18. A Comparison of Dose Metrics to Predict Local Tumor Control for Photofrin-mediated Photodynamic Therapy.
Qiu H; Kim MM; Penjweini R; Finlay JC; Busch TM; Wang T; Guo W; Cengel KA; Simone CB; Glatstein E; Zhu TC
Photochem Photobiol; 2017 Jul; 93(4):1115-1122. PubMed ID: 28083883
[TBL] [Abstract][Full Text] [Related]
19. Photodynamic therapy of actinic keratosis at varying fluence rates: assessment of photobleaching, pain and primary clinical outcome.
Ericson MB; Sandberg C; Stenquist B; Gudmundson F; Karlsson M; Ros AM; Rosén A; Larkö O; Wennberg AM; Rosdahl I
Br J Dermatol; 2004 Dec; 151(6):1204-12. PubMed ID: 15606516
[TBL] [Abstract][Full Text] [Related]
20. The vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid improves the antitumor efficacy and shortens treatment time associated with Photochlor-sensitized photodynamic therapy in vivo.
Seshadri M; Bellnier DA
Photochem Photobiol; 2009; 85(1):50-6. PubMed ID: 18643909
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
